Home » Alnylam Pharmaceuticals, Kyowa Hakko, Intradigm, SiRNAsense, Polyplus-Transfection, Invitrogen, Applied Biosystems, Millipore, Scripps Research Institute

Alnylam Pharmaceuticals, Kyowa Hakko, Intradigm, SiRNAsense, Polyplus-Transfection, Invitrogen, Applied Biosystems, Millipore, Scripps Research Institute

Jun 19, 2008
Premium
Kyowa Hakko Licenses Alnylam RSV Drug Candidate for Asian Market
 
Alnylam Pharmaceuticals this week announced that it has formed an exclusive alliance with Japanese drug maker Kyowa Hakko Kogyo to develop and commercialize the RNAi shop’s phase II respiratory syncytial virus drug ALN-RSV01 in Japan and other Asian markets.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Mouse Fight

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Seeing the Interactions

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

This Week in Science

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

For Millions

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.

What's Popular?

In Gene Silencing/Gene Editing

  1. Researchers Use CRISPR to Explore Genes Relevant to Human Embryonic Development

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.